The human kinome describes a major group of intracellular signalling molecules. In the last few years, many molecules in the group have become targets for therapeutic interventions. Due to the conserved reaction mechanism of catalysis, protein kinases seem well "drugable" by small molecular weight inhibitors, thus opening the chance to novel oral bioavailable drug development. A large number of small molecule weight inhibitors for protein kinases have already been introduced into research and these molecules are extensively analysed in regard to their efficiency, potency and selectivity. Here we summarise the use of small molecule protein kinase inhibitors relevant for acute and chronic inflammation based on their essential role in cellular signaling mechanisms in immune cells such as macrophages, lymphoytes and granulocytes. We describe the progress made to develop inhibitors against Toll-like receptor associated kinases (IRAKs), against the MAPK kinase kinases Cot/Tpl-2 and TAK1, against Inhibitor-B kinases (IKKs), against MAPK kinases (MEKs, MKKs), against MAPKs (ERK2, p38, JNKs) and against their downstream kinases MNK1 and MK2/3. This overview should help to keep up with the fast developing field and the continuously growing number of protein kinase inhibitors.
INTRODUCTION
Human diseases with acute and chronic inflammation, such as eczema and psoriasis, rheumatoid arthritis (RA), inflammatory bowel disease (IBD, in particular Crohn's disease (CD) and ulcerative colitis (UC)), multiple sclerosis (MS), organ transplant rejection and others, still demand better therapies. Although there are many well established drugs on the market, these drugs often fail in patients with severe disease or have major side effects [1] . The recent launchings of biologics such as cytokine neutralising antibodies or soluble receptors (e.g. Anti-TNF alpha, [2] ) represent a major progress in the treatment of chronic inflammatory diseases. However, these promising approaches are limited in their application via injection, still leaving the need for oral drugs preferred by most patients. Hence, the search for promising new drugs and drug targets in inflammation continues with great intensity.
Since any inflammatory response is based on the recognition of inflammatory/danger signals that activate intracellular signalling cascades leading to increased expression of proinflammatory cytokine genes, a signal transduction therapy approach in general seems possible and useful. Ideally, a good target is a signalling molecule that plays a specific role in inflammatory response but is dispensable for other essential cellular signalling events.
A promising class of "drugable" signalling molecules are protein kinases -key factors in signal transduction for the propagation and regulation of immunologic responses. In contrast to proteinprotein interaction, protein kinases are considered to be well "targetable" by small molecular weight compounds which inhibit their catalytic activity or their activation by phosphorylation. However, some specific targeting of protein-protein-interaction by peptides seems also useful, especially in the JNK pathway (see below), and it should be noted that other techniques such as antisene and small interfering RNAi, as well as decoy oligonucleotides and RNA aptamers delivered by viral vectors may be of future relevance. The fact that kinases moved into in the focus as promising drug targets for the therapy of inflammatory and autoimmune diseases is reflected by several excellent reviews [3] [4] [5] [6] . Only a few kinase inhibitors are in clinical use at the moment, mainly in oncology, and most others still require validation or are in early stages of research. Hence, it is still to be seen whether protein kinases are "the major drug targets of the twenty-first century" [7] .
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GENERAL CONSIDERATIONS FOR TARGETING OF PROTEIN KINASES

Target Identification and Validation
Recently, major knowledge has been gained in different issues enabling us to tackle the protein kinase targets systematically: First, the elucidation of the complete human kinome revealed the existence of 518 expressed kinase genes [8] and defines the combinatory biochemical space in which protein kinase inhibitors could act, although it can not be excluded per se that these small molecule inhibitors target other proteins as well. Second, there is at least a partial understanding of how protein kinases function in inflammation [9, 10] . Third, technologies suitable for in vitro and in vivo target validation, inhibitor screening and their structural refinements have been further developed. For example, the model mice with constitutive or conditional gene knockouts of orthologs to human protein kinases have been generated. These mice are valuable tools for the validation of a specific human protein kinase as pharmacological target. Fortunately, 510 orthologs of the human kinases have been identified [10, 11] . However, the absence of a protein kinase in a knockout model has often demonstrated phenotypes different from those due to the presence of an inhibited or a catalytic dead-enzyme. An example is provided by the MAPKAP kinase MK2 knockout mouse, where protein levels for its activator p38 MAPK were also reduced and could be rescued by expression of catalytic-dead MK2 [12] . Hence, knock-in of kinase-dead or hypomorphic kinase mutations may solve such problems and provide useful model systems. Of course, inflammatory mechanisms and cytokine spectra are to a certain degree different between mouse and men and lead to the requirement of further parallel technologies, such as human cell and tissue culture.
One of the most critical steps for the successful exploration of protein kinase inhibitors is the concept validation of the target kinase. More than ten thousand human proteins can exist in phosphorylated isoforms in living cells -in many cases even with multiple phosphorylations. Furthermore, each of the 518 expressed human protein kinases has, at least in average, more than 20 different physiologically relevant substrates. In addition, some substrate proteins can further amplify the signal by interfering with different physiological functions in parallel. Due to many substrates even an absolutely specific inhibitor against a single protein kinase could lead to many different physiological effects representing the "intrinsic specificity" of the target. On the other hand, functionally related kinases exhibit different susceptibility to specific kinase inhibitors and, hence, the effect of inhibition of one kinase with low "intrinsic potency" can be compensated by the non-targeted related kinase. At the end one may speculate that only a small subset of the human kinome will be suited as target for small molecule inhibitors and only a few kinases will be useful targets in inflammation.
State of the art target identification and validation should be performed rather broadly, including analyses of expression pattern in health and disease, in vitro validation using e.g. RNAi technologies and use of KO mice to estimate the potential clinical profile of an pharmacological inhibitor with regard to effects/side effects . Even then there remains a level of uncertaincy with regard to the effects which eventually may be discovered when a compound is tested in animals or even in the patients.
Specificity and Potency of Inhibitors
Beside intrinsic specificity of the target, the specificity of an inhibitor is of equal importance. All compounds tested so far inhibit more than one kinase in a kinome subset of more than 119 enzymes analysed [13] [14] [15] . Some of these inhibitors, such as staurosporine, show a broad spectrum inhibiting more 100 protein kinases with different potency. Recently, 16 clinically relevant kinase inhibitors, which are already approved or still in development, were tested for their specificity against 119 protein kinases spread over the entire kinome [15] . It was found that even the "specific" c-abl tyrosine kinase inhibitor Gleevec and the p38 MAPK inhibitor BIRB-796 (see below) cross-inhibit phylogenetically unrelated kinases with significant potency. This indicates that inhibitor specificity could still be the most important issue. This notion is also supported by proteomic approaches using immobilised small molecule inhibitors for affinity purification of target kinases [16] . In consequence the apparently limited selectivity of most kinase inhibitors available so far can lead to very heterogeneous clinical profiles with regard to effects and side effects in patients.
The wide variety of different small molecule protein kinase inhibitors which have been used in biochemical research labs for many years is characterised by large differences in potency against their targets [3] . Most of the inhibitors act in an ATP-competitive manner and their potency depends on their intrinsic affinity for the ATP-binding pocket and residues in its vicinity in relation to the specific affinity of the kinase for ATP [17] . Since the ATPconcentration in living cells ranges from one to five micromolar, the in vivo potency of an inhibitor can only be estimated from in vitro experiments using comparable ATP-concentrations. In addition, many protein kinases are regulated by ligand-binding or phosphorylation and exist in two conformations, an inactive and an active form with different affinities for ATP making it also important to know which conformation the inhibitor is binding to. Interestingly, a few kinase inhibitors, such as Gleevec or BIRB-796, extend their interaction with the kinase further into regions of the catalytic core including the activation loop and stabilise the inactive conformation of the enzyme leading to higher potency [18, 19] . There are also kinase inhibitors which do not competitively interfere with ATP-binding. The best example is the group of PD98059-related compounds (see below) which binds to the inactive, dephosphorylated conformation of MAPK-kinase 1 (MEK1) preventing its activation by phosphorylation [20, 21] .
TARGETS IN INFLAMMATION
Inflammation results from an intrinsic program of innate immunity. Although inflammation is controlled at different levels in a complex manner, the regulation is based on some essential cellular signaling mechanisms in immune cells including macrophages, lymphoytes, granulocytes and others [10] . These mechanisms include the recognition of extracellular molecular pattern of microbial origin, such as bacterial lipopolysaccharide (LPS), by toll-like receptors (TLRs, reviewed in [22] ) and the subsequent synthesis and release of and signaling by pro-inflammatory "master cytokines" such as tumor necrosis factor (TNF) or interleukin-1 (IL-1). Here   Fig. (1) . Schematic representation of signalling pathways involved in inflammation and innate immunity. Protein kinases are marked in blue and are described in the text. TLR -toll-like receptor, IL1-R -interleukin 1 receptor, NFkB, AP1, IkB, p105 -transcription factors and related proteins, ARE -AU-rich element in the untranslated region of mRNA, TACE -TNF -converting enzyme, ICE -interleukin 1-converting enzyme. [39] we will focus on inhibition of these signaling pathways and discuss the various protein kinases mainly involved. In monocytes LPSinduced biosynthesis of TNF and IL-1 is dependent on both Cot/Tpl2/ERK [23] and TAK1/p38MAPK-pathways [24, 25] , which mainly regulate these cytokines at the post-transcriptional level. Transcription up-regulation of these cytokines is controlled by the NFkB-and JNK-pathways in parallel. Positive feedbacks for increased cytokine synthesis involve the binding of TNF-and IL-1-receptors which activate IRAKs and TAK1 [26] . These different regulatory pathways cooperate in the inflammatory response (summarized in Fig. 1 ) and, unfortunately, many of the key components are also involved in other physiological functions such as regulation of cell proliferation (ERKs), apoptosis and stress response (p38 MAPK and JNKs). Furthermore, there are negative feedback mechanisms which limit the inflammatory response [27] [28] [29] which could lead to opposite effects of inhibition of a single element in these loops. The different approaches to target inflammation by some of the key components of these pathways are summarized below to give an overview on the different small molecule inhibitors in use and development for this purpose. We will discuss the components of the different pathways starting with ERK signaling and subsequently the NFkB and JNK/p38 MAP pathways. However, it should be kept in mind that various cross-talks between these pathways exist.
MKKKS AND COT/TPL-2
In addition to the classical mitogenic stimulation of MEK1/2-ERK1/2 by growth factor receptor, adaptors, c-Ras and kinases of c-Raf-type, some other MAPK kinase kinases are physiologically relevant activators of this pathway as well and could be targets for anti-cancer therapy ( Table 1) . However one of the MKKKs is of special interest also for inflammation ( Table 1) : The human cot (Cancer Osaka thyroid) oncogene was originally identified as a Cterminally truncated transforming protein kinase [30] . It was also described as the Tpl-2 (Tumor progression locus 2) oncogene which is a target for Moloney murine leukemia virus and murine mammary tumor virus provirus insertion in rodents. Provirus insertion gives rise to a truncated molecule with higher stability and constitutive enzymatic activity and induces cell transformation [31] [32] [33] . To reveal the biological function Tpl-2-deficient mice were generated by homologue recombination targeting exon 4 and parts of exon 3 and 5, resulting in complete loss of Tpl-2 protein and kinase activity [23] . The resulting Tpl-2-deficient mice did not exhibit an obvious phenotype under normal conditions, but upon LPS/D-galactosamine-induced endotoxic shock Tpl-2-deficientmice showed partial resistance due to decreased TNF production. The ablation of Tpl-2 does not influence p38 MAPK, JNK, and NFkB activation after LPS challenge in macrophages. Instead, endogenous Tpl-2 is the unique kinase that activates ERK1/ERK2 in response to LPS [23, 34, 35] and contributes to TNF production by facilitating TNF-mRNA transport and translation. Interestingly, LPS-induced activation of Tpl-2 is intimately connected to NFkBsignalling, since p105/NFkB1 exists in a inactive complex together with Tpl-2 which is LPS-dependently phosphorylated by IKK (see Table 7 ) [36] [37] [38] . This interaction demonstrates again the complex regulation of inflammatory response and would strengthen the role of IKKb as a "master target", at least in this pathway.
There are only a few small molecules known at the moment which inhibit MKKK or Cot/Tpl-2-signalling ( Table 1) . The specificity of these compounds seems to be rather low and some act in a ATP-non-competitive manner on phosphorylation of MEKs by MKKKs [39] .
MAP-or ERK Kinases 1 and 2 (MEK 1/2, MKK1/2)
MEK 1 and 2 are closely related dual-specific protein kinases in the classical MAPK-cascade which phosphorylate and activate the MAPKs ERK1 and ERK2 by phosphorylation at a tyrosine and a threonine residue in the activation loop. The first MEK1 and MEK2 inhibitor, PD98059 (see Table 2 ), was identified in an in vitro screen for inhibitors of ERK activation [42, 43] . Shortly thereafter a second inhibitor, U0126, was found in a cell-based screen for inhibitors of phorbol ester-induced activation protein 1 (AP-1)-dependent transactivation [44] . Both inhibitors are non-competitive with ATP and appear to bind to similar sites on MEK1 demonstrated in competition assay. Both U0126 and PD98059 have been shown to block activation of MEK1 by stabilisation of its inactive conformation and, hence, preventing the activation of ERK1 and ERK2. The co-crystal structures of MEK1 and MEK2 with the allosteric inhibitor PD184352 revealed that each have a unique inhibitor-binding pocket adjacent to the MgATP-binding site [45] . Binding of the inhibitor induces several conformational changes in the unphosphorylated MEK1 and MEK2 enzymes that lock them into a closed but catalytically inactive comformation. Secondgeneration MEK1 and MEK2 inhibitors, such as PD184352 and PD325901, display IC 50 -values in the low nanomolar range, enhanced bioavailability, and also appear to work via an allosteric mechanism [46] . Interestingly, there are also ATP-competitive MEK1/2-inhibitors described [47, 48] , but their specificity seems to be lower than the non-competitive inhibitors. MEK 1/2 inhibitors are mainly indicated for treatment of cancer (see Table 2 ) but can principally also be used to block signalling downstream to Tpl-2 [49] . A combination of MEK inhibitors together with p38 MAPK inhibitors is necessary to completely block TNF production in human monocytes [50] .
ERK-Inhibitors
To our knowledge, no highly specific and potent ERK1/2 inhibitors have been reported so far and in most cases the allosteric MEK-inhibitors were used to block downstream activation of ERKs [63] . One of the few direct ERK1/2 inhibitors, FR180204 (see Table 3), was recently identified as a selective and ATP-competitive cell-permeable compound [64] . The crystal structure analysis of the FR180204/ERK2 complex provides structural information that could be helpful in designing inhibitors with higher potency and isoform selectivity. It should be noted that some inhibitors against other protein kinases, such as 5-Iodotubercidin, Olomoucine and SB 220025 (see Table 3 ), also cross-inhibit ERKs. 
N o t F o r D i s t r i b u t i o n
MNK1/2-Inhibitor
The two MAPK-interacting kinases, MNK1/2, are downstream to ERKs and p38 MAPK [69, 70] . Recently, evidence was provided that MNKs play roles in the posttranscriptional regulation of TNF synthesis in T cells by a mechanisms that involve the 3`UTR of its mRNA [71] . Interestingly, inhibition of MNKs by CGP57380 (see Table 4 ) blocks synthesis of endogenous TNF . T cell activation results in the MNK-dependent phosphorylation of a known AU-rich binding protein hnRNP A1 at two MNK sites, and decreases its ability to bind the TNF mRNA in vivo. Binding of MNK to the eIF4G, which interact with eIF4E and the poly(A) binding protein can potentially recruit the MNKs to the 3`UTR and associated ARE-binding proteins such as hnRNP A1. Participation of MNKs (as potential Tpl-2 downstream targets) in mRNA processing [72] could also explain the altered nuclear-cytoplasmic transport of TNF mRNA in TPL2-deficiency [23] .
In residential macrophages, the combination of p38 and ERK1/2 regulate translation of TNF [50] . Since TNF production is inhibited in a concentration-dependent manner by the MNK1 inhibitor CGP57380 also in macrophages [73, 74] , Tpl-2/ERK signalling presumably through MNK1 could contribute to TNF regulation in addition to the well established p38-MK2/3 axis (see below).
IRAK-Inhibitors
The family of interleukin receptor-associated kinases (IRAKs) consists of four related kinases which are involved in intracellular signalling of IL-1R and TLRs (reviewed in [76] ). Only two of them, IRAK-1 and IRAK-4, display catalytic activity and, hence, are relevant for small molecule inhibitor strategies. IRAK-4 kinase activity is involved in receptor mediated activation of IRAK1 which in turn stimulates the TAK1 signalling complex by phosphorylation and translocation [77] leading finally to the activation of NFkB and JNK/p38 MAPKs via IKKs and MKK3,4,6, respectively [78] . Hence, IRAK-1/4 plays a universal role in TLR responses. Both IRAK-1 and -4-deficient mice are viable, fertile and grow normally. IRAK-1 knockout mice and cells show an attenuated cytokine response upon triggering with IL-1 or LPS, but at higher concentrations of the stimuli the effects become smaller suggesting some redundant signalling mechanism [79, 80] . Interestingly, IRAK-1-deficient mice are resistant to septic shock by LPS and IRAK-1-deficient macrophages exhibit impaired LPS-stimulated TNF pro- 
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duction [81] . In contrast to IRAK-1-deficient mice, which were not completely impaired in the cytokine response to IL1 and TLRligands, IRAK-4-deficient mice were severely impaired [82] making IRAK-4 a more suited target for anti-inflammatory therapy. Consequently, a first step in the discovery of potent and selective inhibitors for IRAK-4 was recently made by determining the threedimensional structure of its catalytic domain in complex with the non-specific inhibitor staurosporine and one of the inhibitors below ( Table 5 ) [83] .
TAK1-Inhibitor
One of the best studied MKKKs, transiently activated by proinflammatory stimuli such as TLRs, TNF or IL-1, is TAK1. Genetic ablation of TAK1 in mice demonstrates that a substantial portion of the cellular response to ligands of the adaptive and innate immune system is funnelled through this enzyme [84] [85] [86] . Recently, the compound 5Z-7-oxozeaenol (see Table 6 ), a natural resorcylic lactone of fungal origin, was found to inhibit TAK1 at remarkably low doses in cell-based assays but not MEKK1 or ASK1 [87] . In Tcells, this inhibitor suppressed phorbolester plus calcium ionophore or T-cell receptor-mediated activation. At 100nM it was more effective in blocking IL-2 transcription as assessed in reporter gene assays than the IKK inhibitor SC-514 at 1 M [88] .
IKK-Inhibitors
A central element in the canonical pathway of NFkB signalling is the activation of the I B kinase (IKK) complex which phosphorylates I B at serines 32 and 36 and targets it for proteasomal degradation. This leads to a release and nuclear translocation of NF B where its activity is further controlled by protein kinases that phosphorylate the transactivation domain or other parts of the protein [89] [90] [91] . The two catalytically active subunits of the IKK complex, IKK and IKK , are structurally related but have obviously different physiological function [92, 93] . In the canonical pathway, IKK is the major subunit that transmits proinflammatory signalling through the classical NF-B pathway [92] and that cross talks to Tpl-2 activation [38] . The impact of IKK on inflammation has been convincingly demonstrated using gene modified mice and tool compounds. The overall quality of IKK as target molecule, however, remains to be finally determined since this molecule is broadly involved in many physiological processes too.
Several selective IKK inhibitors ( Table 7) have been described (summarized in [94, 95] ). Most published IKK inhibitors target the ATP-binding site of IKK with the exception of BMS-345541 which is an allosteric inhibitor [96] . In line with their preference for IKK , these compounds have proven anti-inflammatory properties in a variety of animal models [97, 98] .
Here, it should be also noted that, apart from small molecules, peptides (not shown) which block IKK complex formation could effectively inhibit IKK activation [99] .
MKK3-7-Inhbibitors
The dual specific protein kinases MKK3 and MKK6 are the specific upstream activators for p38 MAPK while the kinase MKK7 acts specifically for JNK-activation. When overexpressed, MKK4 activates both p38MAPK and JNKs and its targeted deletion leads to embryonic death at day 14 [111] . MKK5 is a specific activator of ERK5 and probably not involved in the inflammatory response [112] . From targeted deletion of MKK3 and MKK6 in mice it became clear that these two enzymes function differently, at least in part, in different compartments of the immune system [113] . Hence, inhibiting one of these kinases could provide a more specific tool to modulate the immune response compared to inhibition of p38 itself. In the absence of MKK7, stress-dependent JNK activation is greatly reduced in ES cells [114] demonstrating that MKK7 is the major activator of JNKs. Accordingly, MKK7 inhibitors (see Table 8 ) could be of comparable effect as pan-JNK inhibitors. Although the role MKK3, MKK6 or MKK7 in T-cell function is well described, the role of these enzymes on LPS-induced cytokine production of monocytes has not been analysed so far.
JNK-Inhibitors
The first published reversible ATP-competitive inhibitor of JNK, the anthrapyrazolone SP600125 ( Table 9) , inhibits JNK activity in vitro (IC50: 40 nM) and at concentrations above 5 M in cells in vivo [116] . SP600125 displays rather low specificity, since it has also been found to inhibit 13 out of 28 protein kinases with comparable potency [14] and to bind to more than 20 protein kinases with similar affinity [15] . At higher concentrations (50 M) it also inhibits p38 MAPK [116] . However, SP600125 inhibited expression of metalloproteinases in cell-based assays and reduced tissue destruction in rheumatoid arthritis [117] , indicating a certain level of developmental potential. A contribution of JNK2 to metalloproteinase expression and tissue damage in animal models of arthritis was confirmed by analysis of JNK2-deficient mice [118] . SP600125 also synergizes with SB203580 (Table 10 ) and PD98059 ( Table 2) in inhibiting inflammatory genes [119] . Due to the low specificity of SP600125, many other attempts to develop more specific inhibitors have been made. Recent structural analysis of JNK1 in complex with SP600125 revealed this compound mainly contacts hydrophobic sites in the adenine-binding pocket of the ATP-binding site of JNK1 [120] . The results indicate that expanding the structure of SP600125 towards the phosphate-binding site of JNK by polar groups should improve the JNK-specificity of this compound. Meanwhile, inhibitors with IC50 in the low nanomolar range exist (see "Takeda-compound" in Table 9 ), but for most of them no data on specificity are available (further detailed information on chemical structures can be found in reference [121] ).
Similar to the IKK protein complex, protein scaffolding by JIP is necessary for JNK signaling [122] and can be also targeted by cell permeable peptides. (Table 10) , such as SB203580, had been identified as cytokine-suppressive anti-inflammatory drugs before their targets, the p38 MAPKs and , were known [24] . Meanwhile, most of the information on p38 MAPK function comes from the use of p38 inhibitors, such as SB203580 and SB202190. This information should be always carefully treated, since SB203580 also inhibits other protein kinases [15] including enzymes involved in inflammatory response such as RICK [16] . Meanwhile, cohorts of p38 inhibitors have been reported and most of them are ATPcompetitive (reviewed in [125] [126] [127] [128] [129] [130] [131] ). They can be classified into three groups: (i) ATP competitive, imidazole-or pyrrole-based inhibitors, the prototype of which is the 2,4,5-triaryl imidazole (SB203580), (ii) bicyclic heterocyle based inhibitors like the potent and highly selective VX-745 p38 inhibitor and (iii) allosteric N, N'-diarylurea based inhibitors with the prototype BIRB796 [127] . A large number of p38 inhibitors were developed based on the above mentioned prototypes to improve selectivity and better antiinflammatory drug abilities [127] . This was highly supported by parallel structural analysis [132] [133] [134] . Many inhibitors are efficacious in several disease models, including inflammation, arthritis and other joint diseases, septic shock, and myocardial injury (reviewed in [126, 128, 135] ). For example, SB203580, SB220025, SB242235 and R-130823 were effective in murine models of collagen induced arthritis [135, 136] , SB203580, RWJ67657, BIRB796 in the reduction of systemic inflammation; SB 203580 and CNI-1493 in the treatment of Bowel disease and SB 203580 and SB 239063 in brain inflammation and stroke models.
N o t F o r D i s t r i b u t i o n
Although many p38 inhibitors are in development, most seem to be delayed in phase I or II studies by reasons of liver toxicity [130] .
MK2/3-Inhibitors
Downstream to p38 MAPK there are two enzymes designated MAPK-activated protein kinases (MAPKAPKs or MKs), MK2 and MK3 [144] . Deletion of MK2 in mice results in decreased LPSstimulated TNF-production [93] which is further reduced by additional ablation of MK3 [145] . MK2/3 and p38 form a stable complex [146, 147] . Loss of MK2/3 protein also leads to significant reduction of p38 MAPK level in various cells and tissues [12, 145] . However, this is not the primary reason for the observed reduction of cytokine production, since kinase-dead MK2 can restore p38 level, but only catalytically active MK2 can rescue TNF production in macrophages, indicating the importance of MK2 activity for inflammation. Since the effects of loss of MK2/3 activity are quantitatively very similar to the effect of p38 inhibitors, such as SB203580, MK2/3 seem to be the major targets for p38 in this inflammatory pathway. In accordance, MK2-deficient mice show resistance against collagen-induced arthritis [148] . Taking into account that p38 MAPK knockout leads to embryonic lethality N o t F o r D i s t r i b u t i o n [149] and that MK2/3-deficient mice are viable and fertile [145] , inhibition of MK2/3 could be of advantage over p38 inhibitors with regard to side effects.
Small molecule inhibitors for MK2/3 have been developed and are under investigation at the moment (Table 11) . Some have been successfully used in cell culture [150] and in a rat arthritis model (US Patent 2004/0209897A1). The structure of MK2 in complex with an inhibitor (see Fig. 2 , Hillig et al. in press) will clearly facilitate the development of more specific and potent compounds by rational drug design.
Table 12. Kinases as Drug Targets in Inflammation
Challenges / Issues
Balance between immunomodulation and severe immunosuppression (dangerous)
Potential side effects due to other functions, involvement in other physiological processes
Selectivity of compounds
Requirements to be considered as promising
Restricted expression patterns
Modulation of pivotal immune cell populations (e.g. T-cells) Specific pathway inhibition strategies (mainly cytokine signaling)
Profound target validation in vitro and in vivo (e.g. using KO mice)
CONCLUSIONS
Kinases are promising but challenging drug targets for several inflammatory and autoimmune diseases ( Table 12 ). Many small inhibitors against protein kinases involved in inflammation are currently undergoing analyses. Due to the lack of comparable and comprehensive data on specificity and effects in disease models, it is clearly to early to decide which target and which class of inhibitors should be favoured for therapy. However, it becomes obvious that the technology to target protein kinases by small molecules is more sophisticated and that several promising target kinases have been identified to treat acute or chronic inflammation. These compounds include "master regulators", such as IRAK or TAK1, and more specific downstream targets, such as certain MKKs, MNK1 and MK2/3. Depending on the kind of inflammatory disease and the severity, one can imagine targeting kinases alone or even multiple kinases in combination. In addition, progress in targeting proteinprotein-interaction within the signalling complexes and scaffolds or in targeting enzymes involved in other protein modifications, such as ubiquitination, could constitute efficient therapeutic strategies. Fig. (2) . Structure of the catalytic domain of the MAPKAP kinase MK2 in complex with the inhibitor "compound 1" (see Table 11 
N o t F o r D i s t r i b u t i o n
